From accusations of insider trading to a sexual harassment scandal, we saw quite a few controversies in the medtech universe during 2017. Here are eight that really stood out.
Five manufacturing services companies that mostly have a presence in Minnesota’s medtech hub have joined forces to help small to mid-size OEMs start getting their products off the ground.
These companies, devices, and concepts had a tough time in 2017. Here's hoping things look up in 2018.
MD+DI’s editors chose Abbott as the 2017 Medtech Company of the Year, but our readers had a different opinion.
These companies have risen above the rest in 2017. Which one do you think deserves to wear the crown?
What does it take to drive innovation in a corporate environment, particularly when the project team itself is comprised of more than 100 people?
Have a burning question about how to start out in medtech or advance your career in the industry? Submit it here for a chance to receive a free conference pass to BIOMEDevice San Jose.
MD+DI is looking for professionals working in the medical device and diagnostics industry to contribute articles on a variety of topics—and you'll get paid for it.
AdvaMed is working with its Chinese counterpart to strengthen China-U.S. relations to help spur medical device innovation.
With FDA approval for MRI-conditional labeling for the Ellipse implantable cardioverter defibrillator, Abbott is quickly closing an important gap that previously existed in St. Jude’s portfolio.
We’re celebrating brilliant, budding minds in the medical technology field. These innovators, all under 30 years old, have racked up outsized achievements.
Less than a month after FDA alerted doctors of patient deaths related to balloon-based obesity procedures, a newer version of Apollo’s Orbera balloon has been approved in Europe.
Teleflex agreed to pay up to $1.1 billion for NeoTract, a hyper-growth company in the urological device market.